Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API      

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 

HOME >> API >> API List 3 >> Sodium Valproate

Sodium Valproate CAS number 1069-66-5
DRUG DESCRIPTION | DOSAGE SIDE EFFECTS | PRECAUTIONS | INTERACTION |  CONSUMER INFORMATION |  PDF DOWNLOAD |  WORD DOCUMENT |  Details



Molecular Structure



Sodium Valproate

CAS number 1069-66-5

Formula C8H15NaO2
Molecular Weight 166.19
ATC code N03AG01
PubChem 14047
ChemSpider 13428
Chemical data

Mol. mass 166.20 g/mol
Pharmacokinetic data
Bioavailability ?
Protein binding 90–95%
Metabolism 75% by CYP enzymes
Half life 9–18 hours
Excretion 20% excreted as glucuronide

• CAS number 1069-66-5
• Formula C8H15NaO2
• Molecular Weight 166.19
• ATC code N03AG01
• Pub Chem 14047
• Chem Spider 13428

Microbiological Test
Total plate count MAX 1000/g
Yeast&mold MAX 100/g
E.Coli Negative 

IUPAC Name: sodium 2-propylpentanoate | CAS Registry Number: 1069-66-5
Synonyms: Sodium valproate, Valproate sodium, Depakene, Epilim, Convulex, Eurekene, Labazene, Orfiril, Valerin, Natrium valproat, Selenica, Sodium 2-propylpentanoate, Valproic acid sodium salt, Dipropylacetate sodium, Sodium dipropylacetate, Depakene (TN), Selenica (TN), Sodium bispropylacetate, Valproic acid sodium, Valproinsaeure, natrium

Molecular Formula: C8H15NaO2 Molecular Weight: 166.193270 [g/mol]
H-Bond Donor: 0 H-Bond Acceptor: 2
Description   
Sodium valproate is indicated mainly for complex or pure absence seizure, it can also be kinds to treat myoclonia or assist to treat it. Which is white powder, slightly subastringent, soluble to water.

Chemistry
Sodium valproate (INN) or valproate sodium (USAN) is the sodium salt of Valproic acid and is an anticonvulsantanticonvulsant used in the treatment of epilepsy and bipolar disorder, as well as other psychiatric conditions requiring the administration of a mood stabilizer. The intravenous formulations are used when oral administration is not possible.

• MF: C8H15NaO2
• MW: 166.20 g/mol
• Metabolism75% by CYP enzymes
• Half life9-18 hours
• Excretion: 20% excreted as glucuronide

Uses

• Sodium valproate is the widely used an anti-epileptic drug in the pediatric population. Nausea, vomiting, anorexia, amenorrhoea, sedation, tremor, weight gain, alopecia, and hepato-toxicity are the most common side effects of this drug.The hepatotoxicity may manifest in several ways: transient elevation of transaminase values, reversible hyperammonemia with liver disease, or Reye syndrome - like syndrome, or progressive hepatitis.

• Patients with epilepsy who are on sodium valproate have been reported to have low serum carnitine levels and this secondary carnitine deficiency has been reported in the literature. Prolonged treatment with sodium valproate more than other anticonvulsantsanticonvulsants, enhances renal losses of carnitine esters, lowers serum carnitine levels, and results in secondary carnitine deficiency.It also may cause a decrease in serum free carnitine levels by inhibition of plasmalemmal carnitine uptake.

Production

This compound has been obtained by two different ways:
 

• The reaction of dipropylcarbinoldipropylcarbinol with HBr gives 4-bromoheptane, which is treated with KCN to yield 2-propylpentanenitrilepropylpentanenitrile .Finally, this compound is hydrolyzed to the target compound with NaOH or with H2SO4.

• The condensation of cyanacetic acid ethyl ester with propyl bromide by means of sodium propoxide in propanol gives crude dipropylcyanaaceticdipropylcyanaacetic acid ethyl ester, which, without isolation, is hydrolyzed with NaOH in hot water yielding dipropylcyanaceticdipropylcyanacetic acid .The decarboxylationdecarboxylation of dipropylcyanaceticdipropylcyanacetic acid at 140-

Safety Profile

All antiepilepic medications have been shown to be associated with higher risks of fetal abnormalities (mostly for spina bifida) since at least 1983 with the risks being related to the strength of medication used and use of more than one drug.Valproate has also been recognised as sometimes causing a specific facial changes ("facial phenotype") termed "fetal valproate syndrome".Sodium valproate has been associated with the rare condition paroxysmal tonic upgaze of childhood, also known as Ouvrier-Billson syndrome, from childhood or fetal exposure (this condition resolved after discontinuing valproate therapy)

Mechanism Of Toxic Effects

Valproate is a drug with anticonvulsant activity against a wide range of seizure types and appears to be well tolerated at therapeutic doses. In therapeutic use valproate's action may be related to altered turnover of GABA and actions on voltage sensitive sodium channels. The mechanisms involved in toxicity are unclear. It appears to have teratogenic effects in therapeutic doses.

Information Associated with Product:
DRUG DESCRIPTION DOSAGE SIDE EFFECTS PRECAUTIONS INTERACTION CONSUMER INFORMATION
PDF DOWNLOAD	WORD DOCUMENT	Details
Product Enquiry Product Quotation Sample Request Place Your Order

    Investor Relations    Feedback     Contact Worldwide    Sitemap